Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Exosome redux

Nature Biotechnology volume 37, pages 1395–1400 (2019)Cite this article

Adult stem cell companies are pivoting their businesses to commercialize exosomes as therapeutics.

Companies previously developing mesenchymal stem cells (MSCs) and cardiac progenitors for the heart and neural stem cells for the brain are now targeting the differing capabilities of exosomes derived from these cell types for their respective therapeutic areas. While progress in understanding exosome biology continues apace, large gaps remain in our understanding of their biogenesis, secretion, target cell uptake and function. What’s more, to turn these natural products into standardized treatments, companies must wrestle with batch consistency during manufacture, efficient cargo loading for drug delivery applications, and scale-up issues during product development. As they scramble to address these hurdles, the nascent sector anxiously awaits feedback from drug regulators as to how they will view this new treatment modality.

Table 1 Companies with EV products in development
Full size table

Your institute does not have access to this article

Relevant articles

Open Access articles citing this article.

Access options

Buy article

Get time limited or full article access on ReadCube.

$32.00

Buy

All prices are NET prices.

Fig. 1: Different EV subtypes are depicted together with other co-isolated particles.

Author information

Authors and Affiliations

  1. Haddon Township, NJ, USA

    Mark Zipkin

Authors
  1. Mark Zipkin
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Zipkin, M. Exosome redux. Nat Biotechnol 37, 1395–1400 (2019). https://doi.org/10.1038/s41587-019-0326-5

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41587-019-0326-5

Further reading

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing